Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals

Jean-Matthieu L'Orphelin; Angélique Da Silva; Jean Cabon; Joachim Alexandre; Charles Dolladille

doi:10.1136/bmjopen-2024-091708

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Log out
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Archive

For authors

About

Browse by collection
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

You are viewing from: Agence Bibliographique de l Enseignement Superieur (ABES)

Article metrics

PDF

PDF +
Supplementary
Material

Oncology

Original research

Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals

Online download statistics by month:

Online download statistics by month: December 2024 to June 2025

	Abstract	Full	Pdf
Dec 2024	945	961	173
Jan 2025	324	323	70
Feb 2025	145	143	43
Mar 2025	235	233	60
Apr 2025	122	114	43
May 2025	262	263	53
Jun 2025	25	25	18
Total	2058	2062	460

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online download statistics by month:

Online download statistics by month: December 2024 to June 2025

Read the full text or download the PDF:

Log in using your username and password